Eagle Strategies LLC Has $1.55 Million Stock Position in iShares Biotechnology ETF $IBB

Eagle Strategies LLC cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 4.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,239 shares of the financial services provider’s stock after selling 561 shares during the quarter. Eagle Strategies LLC’s holdings in iShares Biotechnology ETF were worth $1,548,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of IBB. Ramirez Asset Management Inc. acquired a new stake in iShares Biotechnology ETF in the first quarter valued at about $26,000. Berkshire Money Management Inc. acquired a new stake in iShares Biotechnology ETF in the second quarter valued at about $28,000. Financial Gravity Asset Management Inc. acquired a new stake in iShares Biotechnology ETF in the first quarter valued at about $30,000. Woodside Wealth Management LLC acquired a new stake in iShares Biotechnology ETF in the first quarter valued at about $31,000. Finally, CX Institutional acquired a new stake in iShares Biotechnology ETF in the first quarter valued at about $32,000. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Up 1.0%

NASDAQ:IBB opened at $151.99 on Thursday. The stock’s 50-day simple moving average is $140.21 and its 200 day simple moving average is $130.36. iShares Biotechnology ETF has a twelve month low of $107.43 and a twelve month high of $153.01.

iShares Biotechnology ETF Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 19th. Shareholders of record on Tuesday, September 16th were given a $0.0828 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $0.33 annualized dividend and a yield of 0.2%.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.